Keith Martin has enjoyed a successful 30+ year career in both large and early stage pharmaceutical/biotech companies holding senior positions in R&D and corporate & business development as well as both executive and non-executive Board positions. His management and leadership roles have been in UK, Belgium, USA & Spain. He has raised more than €40 M in equity and non-dilutive funding for early stage companies. In addition, Keith has developed products from bench to market and realised value through significant licensing deals. He has also participated in venture investment. CEO of Apitope, a biotech researching & developing antigen specific immunotherapeutic peptides for autoimmune diseases, since April 2006. Led the completion of 2 successful Phase I clinical trial of ATX-MS-1467 in MS patients, Closed financing of €10 M (Series A in Oct 08) and €12 M(Series B in Sept 15) and a €150 M+ licensing deal in Jan 2009. Established R&D labs in UK and Belgium with more than 20 staff. Prior to Apitope, founder and president of KetoCytonyx Inc responsible for securing seed and Series A financing of €4.6 million and completed a Phase I lead programme. Previously, BTG’s Global Director of Life Sciences responsible for an extensive portfolio of product candidates and licensee marketed products. As Deputy Head of Biology at BASF Pharma, he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval in USA and UK. Keith began his research career as a PhD student at the University of Bath; then held a Wellcome Trust Fellowship in Mental Health at Nottingham University Medical School in addition to a NATO Exchange Fellowship to Princeton University Psychology Department. He has served as Visiting Professor in Neuroscience at the University of Sunderland and has an extensive list of publications and patents.

Chief Executive Officer @ From April 2006 to Present (9 years 9 months) Board Member @ From January 2012 to December 2013 (2 years) London, United KingdomInvestment Advisory Committee Member @ From September 2000 to August 2013 (13 years)

Dame Alice Owen's Keith Martin is skilled in: Clinical Trials, Research, Pharmaceutical Industry, Clinical Development, Intellectual Property, Business Strategy, Strategic Planning, Licensing, Business Development, Project Management, Negotiation, Due Diligence, Neuroscience, Corporate Governance, Directors' Duties